Evotec SE (NASDAQ:EVO – Get Free Report) saw a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 54,000 shares, an increase of 2,060.0% from the January 15th total of 2,500 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 65,100 shares, the days-to-cover ratio is presently 0.8 days.
Wall Street Analyst Weigh In
Separately, Royal Bank of Canada raised shares of Evotec from a “sector perform” rating to an “outperform” rating in a research report on Thursday, January 18th.
Evotec Trading Up 2.3 %
Hedge Funds Weigh In On Evotec
An institutional investor recently bought a new position in Evotec stock. Quadrant Capital Group LLC acquired a new position in Evotec SE (NASDAQ:EVO – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,130 shares of the company’s stock, valued at approximately $25,000. Institutional investors own 0.39% of the company’s stock.
Evotec Company Profile
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.
- Five stocks we like better than Evotec
- 3 Tickers Leading a Meme Stock Revival
- 3 attractive stocks that insiders are buying
- How to Invest in Grocery Stores
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- 3 Small Caps With Big Return Potential
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.